Heteroarylaminosulfonamide CFTR Modulators for Misfolding Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no cure for cystic fibrosis, a fatal disease caused by functional deficiency of the CFTR protein, and existing treatments do not effectively address the underlying channel dysfunction or misfolding issues, leading to chronic lung infections and organ dysfunction.
Innovation Solution
Development of 6-membered heteroarylaminosulfonamide compounds that act as CFTR modulators, correcting misfolded CFTR protein conformation and enhancing its function, thereby treating diseases mediated by deficient CFTR activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CFTR modulators are developed to correct misfolded CFTR protein, then CFTR function is improved, but the complexity of drug design and development increases
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical parameters in the small molecule structure (such as substituent groups, ring structures, and molecular weight) to optimize CFTR correction activity. This allows the development of modulators with improved efficacy while maintaining manageable design complexity through structured chemical space exploration.
Solution Approach 2:
The small molecule CFTR modulators act as intermediaries that mediate between the misfolded CFTR protein and the cellular quality control machinery. These compounds bind to specific domains of CFTR (such as NBD1 or ICL4) to stabilize the protein structure, promote proper folding, and facilitate trafficking to the cell surface, thereby improving CFTR function without requiring direct manipulation of the complex folding machinery.
2Ease of operation
If existing treatments are used to manage CFTR deficiency symptoms, then symptom management is provided, but the underlying channel dysfunction and misfolding issues are not effectively addressed
Solution Approach 1:
The patent applies preliminary action by developing compounds that correct CFTR misfolding and restore channel function before symptoms can develop or worsen. By stabilizing the CFTR protein structure early in the disease process and promoting proper folding and trafficking, these modulators address the root cause of channel dysfunction rather than merely managing downstream symptoms, thereby providing both preventive and therapeutic benefits.
Data Source
AI summary
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.